Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMedTM 670G hybrid closed-loop system in simulated trials compared to …

B Grosman, D Wu, N Parikh, A Roy… - Computer Methods and …, 2021 - Elsevier
Introduction Medtronic has developed a virtual patient simulator for modeling and predicting
insulin therapy outcomes for people with type 1 diabetes (T1D). An enhanced simulator was …
被引用次数：10 相关文章

Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMedTM 670G hybrid closed-loop system in simulated trials compared to …

B Grosman, D Wu, N Parikh, A Roy… - … and programs in …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction Medtronic has developed a virtual patient simulator for modeling and predicting
insulin therapy outcomes for people with type 1 diabetes (T1D). An enhanced simulator was …

Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMedTM 670G hybrid closed-loop system in simulated trials compared to …

B Grosman, D Wu, N Parikh, A Roy… - … and Programs in …, 2021 - europepmc.org
Methods Sixty-seven participants' PK profiles were generated per type of insulin (Total of
134 PK profiles). 7,485 virtual patients' PK measurements was matched with one of the 67 …